6450 Ultrasound System (MyLabE80); 6450 Ultrasound System (MyLabE85)

The Esaote 6450 Ultrasound System, including MyLabE80 and MyLabE85 models, is a general-purpose diagnostic ultrasound system designed for various medical imaging applications. Its substantial equivalence to legally marketed devices was affirmed through comprehensive non-clinical testing of acoustic output, biocompatibility, and safety standards, incorporating new features like the XStrain LA for advanced left atrium analysis and the IHX 6-25 probe.

A communication from the U.S. Food & Drug Administration dated May 16, 2025, informed Esaote S.p.A. of the successful review of their 6450 Ultrasound System, which encompasses the MyLabE80 and MyLabE85 models. This Class II Ultrasonic Pulsed Doppler Imaging System was determined to be substantially equivalent to existing legally marketed predicate devices for its specified indications for use. Consequently, Esaote S.p.A. has been authorized to market the device, contingent upon adherence to general control provisions, including annual registration, device listing, good manufacturing practices, and appropriate labeling. The 6450 Ultrasound System is designed as a general-purpose diagnostic ultrasound platform, with the MyLabE80 and MyLabE85 models primarily differentiated by their license configurations. Key new features integrated into the system include XStrain LA, an advanced processing package tailored for Left Atrium analysis, and a new IHX 6-25 probe. The system's safety and performance were comprehensively assessed through various non-clinical tests, covering aspects such as acoustic output, biocompatibility, cleaning and disinfection efficacy, and compliance with thermal, electrical, electromagnetic, and mechanical safety standards. These evaluations confirmed the device's conformity with applicable medical device safety and performance standards, eliminating the need for clinical studies to support the substantial equivalence determination.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical benefits does the new XStrain LA advanced processing package offer for Left Atrium analysis compared to previous methods or devices?; How does the IHX 6-25 probe enhance diagnostic capabilities or patient comfort compared to other probes available for the system?; Given that no clinical studies were required, what were the most critical non-clinical test results that strongly supported the substantial equivalence determination for this system?; Are there any specific patient populations or clinical applications where the 6450 Ultrasound System, particularly with its new features, demonstrates a notable advantage?; What are the long-term data collection plans, if any, for post-market surveillance of the 6450 Ultrasound System regarding its performance and safety in real-world clinical settings?